Multiple Myeloma

Minimal (Measurable) Residual Disease (MRD) in multiple myeloma (MM) refers to the disease burden that remains following therapeutic intervention that may be detectable by highly sensitive assays. It has emerged as one of the strongest prognostic …

Venous thromboembolism (VTE) poses a significant challenge in the context of multiple myeloma, with an incidence of up to 10% in newly diagnosed patients and varying frequency in the relapsed/refractory setting. Accurate VTE risk assessment and …

Despite the development of various therapeutic agents, multiple myeloma remains incurable. Recently, T-cell redirected immunotherapy has become a promising strategy for the treatment of refractory myeloma. Clinical trials using chimeric antigen …

Improvement in the therapeutics for multiple myeloma (MM) has been continuously developed owing to the application of novel drugs and technologies in the last 20 years. The standard first-line therapy for MM consists of a three-drug induction …

Multiple myeloma (MM), the second most common hematological malignancy, is an incurable clonal plasma cell dysplasia, which mainly occurs in the elderly population (Liu et al. 2019 ). In past decades, with the emerging novel agents and laboratory …

Patients diagnosed with lymphoma or multiple myeloma are at elevated risk of venous thromboembolism (VTE). Optimum risk stratification and effective thromboprophylaxis can only be achieved through the development of a multiple-specific risk score …

Minimal (Measurable) Residual Disease (MRD) in multiple myeloma (MM) refers to the disease burden that remains following therapeutic intervention that may be detectable by highly sensitive assays. It has emerged as one of the strongest prognostic …

Evidences shows that T helper 17 (Th17) and regulatory T (Treg) cells imbalance plays a critical role in bone lesions of MM patients. Therefore, regulating the Th17/Treg imbalance may be beneficial for bone lesions in MM. Ten MM mice complicated …